SCHOTT Pharma AG & Co. KGaA Overview
Pro stress-test →SCHOTT Pharma designs advanced drug containment solutions and drug delivery systems for the pharmaceutical and biotech industries. Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023. The company is a critical infrastructure provider for injectable pharmaceuticals globally.
Strategic Profile
Pro stress-test →SCHOTT Pharma is a leading provider of drug containment and delivery solutions, specializing in primary packaging for injectable pharmaceuticals, with science-based products such as prefillable glass and polymer syringes, cartridges, vials, ampoules, and innovative systems. With approximately 4,700 employees operating 16 GMP-compliant manufacturing sites across Europe, North and South America, and Asia, the firm holds over 1,000 in-house patents and targets climate neutrality by 2030.
Competitive Landscape
Pro stress-test →SCHOTT Pharma operates in the specialized pharmaceutical primary packaging market with limited direct competitors due to high barriers to entry. Key competitors include Gerresheimer (glass vials/cartridges), Nippon Glass (Japan-based), and West Pharmaceutical Services (polymer-based delivery systems). SCHOTT's competitive advantage derives from integrated glass expertise, global manufacturing footprint, and comprehensive product portfolio serving injectable drug needs.
Industry Context
SCHOTT Pharma AG & Co. KGaA operates in Pharmaceutical Packaging & Drug Delivery Systems - Medical Instruments & Supplies.
Key facts
Founded: 1884 · Headquarters: Mainz, Germany · Employees: 4,775 · Revenue: €986M (FY2025)